Big Pharma owns Tennessee, 2nd most medicated state per

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles Budd Kind #15544
Big Pharma owns Tennessee, 2nd most medicated state per capita in the union. Follow the money.

Forbes study that ranked Tennessee as the second-most medicated state in the nation. The study revealed that people in Tennessee take an average of about 17 prescriptions a year. The national average is 11.6 prescriptions a person.

According to the ProPublica analysis, drug company payments totaled at least $7.9 million to Tennessee-based doctors in 2009 and 2010 which ranks Tennessee as the 11th-highest statewide total found in the analysis.

Of all 535 members of Congress (100Senate / 435House) Sen. Lamar Alexander of Tennessee is the fourth highest recipient of  2013-2014 Big Pharma political campaign contributions ($93,000, not counting corporate donations to the party or PACS). Sen. Mitch McConnell of Kentucky received the highest amount from Big Pharma,  $112,700 (not counting corporate donations to the party or PACS).  


Dr. Jon W. Draud, the medical director of psychiatric and addiction medicine at two Tennessee hospitals ... During the last four years, the 47-year-old Draud has earned  more than $ 1 million for delivering promotional talks and consulting for seven drug companies. Draud’s $1 million in drug company earnings is probably a minimum figure. Some of the seven companies he represented have reported their payouts for only a short time. And Draud has  separately disclosed ties with at least four additional companies that haven’t revealed how much they pay speakers. By a wide margin, Draud’s earnings make him the best-paid speaker in ProPublica’s Dollars for Docs database , which has been updated to include more than $2 billion in payments from 15 drugmakers for promotional speaking, research, consulting, travel, meals and related expenses from 2009 to 2012.
http://www.alternet.org/doctors-paid-millions...big-pharma

2010
The Tennessean reported last week that Tennessee doctors rank in the top dozen nationally for the amount of money they’ve received in the past two years promoting drugs for the pharmaceutical industry. This controversial finding about drug payments to doctors in Tennessee comes on the heels of the release of a Forbes study that ranked Tennessee as the second-most medicated state in the nation. The study revealed that people in Tennessee take an average of about 17 prescriptions a year. The national average is 11.6 prescriptions a person. To get their medications, Tennesseans spent about $6.1 billion at retail pharmacies in 2009, according to the Henry J. Kaiser Family Foundation.

It is concerning to some that doctors in Tennessee are being heartily reimbursed for engaging in pharmaceutical promotional speaking events, whilst the public pays so much money for medicine. ProPublica, an independent nonprofit journalism source, began compiling a database called Dollars for Docs in October which documents pharmaceutical payments to doctors for speaking, consulting, and other promotional activities. The list includes information from Eli Lilly & Co., AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Cephalon for various periods of 2009 and 2010.

According to the ProPublica analysis, drug company payments totaled at least $7.9 million to Tennessee-based doctors in 2009 and 2010, which ranks Tennessee as the 11th-highest statewide total found in the analysis. The Tennessean reports that Dr. Hal Roseman, a Nashville cardiologist, and Dr. Jon W. Draud, a Nashville psychiatrist, have received payments approaching a quarter of a million dollars. Dr. Jan Brandes, who heads the Nashville Neuroscience Group at Saint Thomas Health Services, netted $111,150 in outside income over the past two years, mostly, according to The Tennessean, from speaker fees paid by drug company GlaxoSmithKline. She is a much sought-after headache specialist who gives seminars sponsored by the drug companies for whom she conducts trials. She defends these seminars by claiming she is there to educate others and not to push certain drugs. The response was similar from other doctors that The Tennessean reported make over hundreds of thousands of dollars in payments for speaker engagements: they defend these activities as being ways to publicize new ideas about how to treat a disease. The sentiment seems to be that compensation does not necessarily indicate bias.

Cardiologist Hal Roseman told The Tennessean that his patients are well aware of his involvement with the pharmaceutical industry and appreciate his knowledge of the studies of possible treatment agents. In apparent contradiction to this response, a poll of 1,250 adults conducted by the Consumer Reports National Research Center showed that half of respondents said they’d be concerned about the advice of a doctor who took as little as $500 from the pharmaceutical industry. 75 percent said they’d be concerned about doctors who accepted up to $25,000. The numbers in this case in Tennessee are generally $100,000 upwards of these numbers. Consumer advocates view compensation for physicians by pharmaceutical companies as an endangerment of the integrity of medicine and a potential addition to the US’s already high health-care costs.

Another physician in The Tennessean article says that her consulting work has nothing to do with her patients. Perhaps there are potential benefits to these relationships- physicians working with the drug companies might share expert information from work in the field. Pharmaceutically sponsored research has, it must be acknowledged, meant huge leaps in advances in disciplines like neurology.

The increased skepticism about ties to the pharmaceutical companies has led to more stringent policies on conflicts of interest. Vanderbilt University Medical Center implemented a policy last year that more tightly regulates disclosure from doctors and others about paid speaking engagements, consulting work and industry reimbursements for travel expenses. Increased scrutiny of the pharmaceutical industry means more transparency for consumers to make choices for themselves.

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 6

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 6

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 6

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 10

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 14

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

AllenComm Receives Esteemed Recognition in eLearning Field

Updated Category News Views 137

AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...

Continue Reading
Unlocking AI Potential with New Relic and DeepSeek's Integration

Updated Category News Views 197

New Relic and DeepSeek: A Game-Changing Integration for AI New Relic, a leading company in Intelligent Observability, has announced an innovative integration with DeepSeek. This groundbreaking observability solution aims to simplify AI monitoring, making AI technology more accessible and efficient for businesses around the world. By leveraging this integration, companies...

Continue Reading
Zombie Foreclosures Decline as Housing Market Thrives

Updated Category News Views 67

Understanding Zombie Foreclosures in Today's Housing Market In recent months, there has been a notable shift in the dynamics of the housing market, particularly regarding the phenomenon of zombie foreclosures. As the nation's economy continues to recover and housing prices soar, the prevalence of properties in foreclosure that have been abandoned by their owners is...

Continue Reading
Knightscope Partners with TS&L for New Emergency Devices

Updated Category News Views 83

Knightscope Partners for Public Safety Innovation Knightscope, Inc. (NASDAQ: KSCP), known for its pioneering contributions in robotics and artificial intelligence, is excited to announce a new collaboration with its Authorized Partner, Transportation Solutions & Lighting, Inc. (TS&L). This partnership leads to the ordering of 37 Emergency Communication Devices (ECDs)...

Continue Reading
Fetch Market Launches Same-Day Grocery Delivery in Houston

Updated Category News Views 185

Fetch Market Expands Grocery Delivery Services Fetch has officially launched Fetch Market in Houston, a game-changing service created specifically for apartment communities. This initiative offers same-day delivery of groceries and essential items, enabling residents to have snacks and household necessities brought right to their doorsteps in just four hours or less....

Continue Reading